The groundbreaking success of the copyright undeniably reshaped the pharmaceutical landscape, but investing in companies primarily reliant on unbranded versions presents a challenging picture. Despite early earnings were impressive, the expiration of patents and the appearance of less expensive alternatives have diminished the customer base. Con… Read More